InvestorsHub Logo
Followers 12
Posts 1099
Boards Moderated 0
Alias Born 06/07/2018

Re: None

Tuesday, 11/06/2018 1:03:21 AM

Tuesday, November 06, 2018 1:03:21 AM

Post# of 83403
What if the CVSI-007 patent passed? --Since it's still on appeal and all? Wouldn't that be a great treatment for smokers all over the world? What if a major pharmaceutical company partnered with us afterwards? --Or a tobacco company? --How nice would a smoking cessation agent look in say Altria's portfolio as an SBM. We could easily get swallowed up since CVSI is a public company.

With a GRAS Self-Affirmation; we are second to none. Plus CBD is the best anywhere there is, and it's shipped all over the country. Our revenues should be nice if all the trends and reports of Plus CBD selling out in stores are accurate. What if we reached Charlotte Webb's market cap? There is no reason not to. Citron Research also failed on Aug. 20th, 2018 to disclose to investors that the patent in question is still pending. That's negligent misrepresentation.

We may have NASDAQ and Farm Bill passage soon. That would be access to more capital; the Farm Bill would allow CVSI to make CBD from the entire hemp plant locally --not just from the sticks, seeds, and stems. Also, it would remove ambiguity. Risk averse investors would hop in and so would big corporations. I think this is a $200 stock by 2022.

The market penetration is so minimal. The trends suggest a forecast for lower risk. The legal system is starting to move our way. The people have spoken. We are no where near full saturation of the market segment --which could be everybody and animals. CBD has tremendous value, and its impossible to ignore. "The cat's out of the bag," if you will. We could easily hit $25 by the end of the year as a higher PE ratio would hold with passage of either the Farm Bill or NASDAQ --judging by analysts' outlook for 35+ accumulating interest potential for the CBD industry as a whole --and the Tilray effect. If it was 100% legit by way of Farm Bill 2018 passage --with no ambiguity, we could become the size of a blue chip stock very quickly.